论文部分内容阅读
CD33在90％急性髓系白血病(AML)的原始细胞表面表达,为AML的特异性治疗提供了理想靶点。CD33单抗通过补体介导的细胞毒作用和抗体介导的细胞毒作用产生抗肿瘤效应;并且通过与放射性核素、细胞毒药物偶联形成免疫复合物,从而增强对白血病细胞的杀伤作用。本文综述了近年来CD33单抗在基础和临床研究中的进展。
CD33 is expressed on the primary cell surface of 90% of acute myeloid leukemias (AML), providing an ideal target for the specific treatment of AML. CD33 mAb produces antitumor effects through complement-mediated cytotoxicity and antibody-mediated cytotoxicity and enhances the killing of leukemic cells by conjugating with radionuclides and cytotoxic drugs to form immune complexes. This article reviews the progress of CD33 monoclonal antibodies in basic and clinical studies in recent years.